USD 6.78
(-3.9%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 59.69 Million USD | 150.66% |
2022 | 23.81 Million USD | -11.19% |
2021 | 26.81 Million USD | 37.13% |
2020 | 19.55 Million USD | 39.28% |
2019 | 14.04 Million USD | 67.35% |
2018 | 8.39 Million USD | 81.48% |
2017 | 4.62 Million USD | 35.33% |
2016 | 3.41 Million USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
2010 | - USD | 0.0% |
2009 | - USD | 0.0% |
2008 | - USD | 0.0% |
2007 | - USD | 0.0% |
2006 | - USD | 0.0% |
2005 | - USD | 0.0% |
2003 | - USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | 81.32 Million USD | 33.84% |
2024 Q1 | 60.75 Million USD | 1.78% |
2023 Q1 | 27 Million USD | 13.39% |
2023 Q2 | 51.38 Million USD | 90.27% |
2023 Q3 | 56.93 Million USD | 10.81% |
2023 Q4 | 59.69 Million USD | 4.85% |
2023 FY | 59.69 Million USD | 150.66% |
2022 Q4 | 23.81 Million USD | 79.45% |
2022 Q2 | 20.87 Million USD | -14.16% |
2022 Q3 | 13.27 Million USD | -36.43% |
2022 Q1 | 24.32 Million USD | -9.3% |
2022 FY | 23.81 Million USD | -11.19% |
2021 Q3 | 22.07 Million USD | -8.36% |
2021 FY | 26.81 Million USD | 37.13% |
2021 Q2 | 24.08 Million USD | 28.11% |
2021 Q4 | 26.81 Million USD | 21.5% |
2021 Q1 | 18.8 Million USD | -3.86% |
2020 FY | 19.55 Million USD | 39.28% |
2020 Q1 | 12.83 Million USD | -8.62% |
2020 Q2 | 12.97 Million USD | 1.15% |
2020 Q3 | 15.76 Million USD | 21.48% |
2020 Q4 | 19.55 Million USD | 24.03% |
2019 Q3 | 9.15 Million USD | -11.94% |
2019 Q1 | 8.16 Million USD | -2.66% |
2019 FY | 14.04 Million USD | 67.35% |
2019 Q2 | 10.39 Million USD | 27.28% |
2019 Q4 | 14.04 Million USD | 53.39% |
2018 Q4 | 8.39 Million USD | 32.94% |
2018 Q3 | 6.31 Million USD | -18.77% |
2018 Q2 | 7.76 Million USD | -3.73% |
2018 Q1 | 8.07 Million USD | 74.56% |
2018 FY | 8.39 Million USD | 81.48% |
2017 Q1 | 3.69 Million USD | 8.26% |
2017 FY | 4.62 Million USD | 35.33% |
2017 Q4 | 4.62 Million USD | -36.43% |
2017 Q3 | 7.27 Million USD | 84.19% |
2017 Q2 | 3.94 Million USD | 6.76% |
2016 Q1 | - USD | 0.0% |
2016 Q3 | 3.25 Million USD | 1575.77% |
2016 Q4 | 3.41 Million USD | 5.08% |
2016 FY | 3.41 Million USD | 0.0% |
2016 Q2 | 194 Thousand USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2014 Q3 | - USD | -100.0% |
2014 Q4 | - USD | 0.0% |
2014 Q2 | 1.00 USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q1 | 1.00 USD | 0.0% |
2013 Q3 | - USD | -100.0% |
2013 Q4 | - USD | 0.0% |
2013 Q1 | 1.00 USD | 0.0% |
2013 Q2 | 1.00 USD | 0.0% |
2013 FY | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q1 | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2011 Q2 | - USD | 0.0% |
2011 FY | - USD | 0.0% |
2011 Q4 | - USD | 0.0% |
2011 Q3 | - USD | 0.0% |
2011 Q1 | - USD | 0.0% |
2010 Q4 | - USD | 0.0% |
2010 FY | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 Q1 | - USD | 0.0% |
2009 FY | - USD | 0.0% |
2009 Q4 | - USD | 0.0% |
2009 Q3 | - USD | 0.0% |
2009 Q2 | - USD | 0.0% |
2009 Q1 | - USD | 0.0% |
2008 Q3 | - USD | 0.0% |
2008 Q1 | - USD | 0.0% |
2008 Q4 | - USD | 0.0% |
2008 Q2 | - USD | 0.0% |
2008 FY | - USD | 0.0% |
2007 FY | - USD | 0.0% |
2007 Q3 | - USD | 0.0% |
2007 Q2 | - USD | 0.0% |
2007 Q1 | - USD | 0.0% |
2007 Q4 | - USD | 0.0% |
2006 FY | - USD | 0.0% |
2006 Q4 | - USD | 0.0% |
2005 FY | - USD | 0.0% |
2005 Q4 | - USD | 0.0% |
2003 FY | - USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
uniQure N.V. | 12.02 Million USD | -396.474% |
Agios Pharmaceuticals, Inc. | 19.07 Million USD | -212.938% |
Atara Biotherapeutics, Inc. | 9.7 Million USD | -515.042% |
bluebird bio, Inc. | 22.91 Million USD | -160.465% |
Cara Therapeutics, Inc. | 2.82 Million USD | -2016.129% |
Imunon, Inc. | - USD | -Infinity% |
Editas Medicine, Inc. | - USD | -Infinity% |
IQVIA Holdings Inc. | - USD | -Infinity% |
Mettler-Toledo International Inc. | 385.86 Million USD | 84.529% |
Myriad Genetics, Inc. | 20.1 Million USD | -196.995% |
Neurocrine Biosciences, Inc. | 38.3 Million USD | -55.864% |
Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 22.881% |
Verastem, Inc. | - USD | -Infinity% |
Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.283% |
Waters Corporation | 516.23 Million USD | 88.436% |
Thermo Fisher Scientific Inc. | 5.08 Billion USD | 98.827% |
Biogen Inc. | 2.52 Billion USD | 97.638% |
Nektar Therapeutics | 16.1 Million USD | -270.76% |
Perrigo Company plc | 1.14 Billion USD | 94.768% |
Dynavax Technologies Corporation | 53.29 Million USD | -12.021% |
Illumina, Inc. | 587 Million USD | 89.83% |
Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Iovance Biotherapeutics, Inc. | 10.37 Million USD | -475.55% |
Heron Therapeutics, Inc. | 42.11 Million USD | -41.762% |
Unity Biotechnology, Inc. | - USD | -Infinity% |
BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 94.608% |
Sangamo Therapeutics, Inc. | - USD | -Infinity% |
Evolus, Inc. | 10.99 Million USD | -442.79% |
Adicet Bio, Inc. | - USD | -Infinity% |
Aclaris Therapeutics, Inc. | - USD | -Infinity% |
Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 97.687% |
Esperion Therapeutics, Inc. | 65.62 Million USD | 9.032% |
FibroGen, Inc. | 41.56 Million USD | -43.621% |
Agilent Technologies, Inc. | 1.03 Billion USD | 94.21% |
OPKO Health, Inc. | 65.69 Million USD | 9.134% |
Homology Medicines, Inc. | - USD | -Infinity% |
Geron Corporation | - USD | -Infinity% |
Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 33.036% |
Exelixis, Inc. | 17.32 Million USD | -244.605% |
Viking Therapeutics, Inc. | - USD | -Infinity% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | - USD | -Infinity% |
Zoetis Inc. | 2.56 Billion USD | 97.672% |
Axsome Therapeutics, Inc. | 15.13 Million USD | -294.424% |
Abeona Therapeutics Inc. | -2.44 Million USD | 2542.553% |
Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 91.92% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -110.012% |
Sarepta Therapeutics, Inc. | 322.85 Million USD | 81.51% |
Corcept Therapeutics Incorporated | 7.73 Million USD | -672.264% |
Halozyme Therapeutics, Inc. | 127.6 Million USD | 53.217% |
Blueprint Medicines Corporation | 21.22 Million USD | -181.28% |
Insmed Incorporated | 83.24 Million USD | 28.291% |
TG Therapeutics, Inc. | 39.82 Million USD | -49.903% |
Incyte Corporation | 62.97 Million USD | 5.202% |
Emergent BioSolutions Inc. | 328.9 Million USD | 81.85% |